Spectral Medical Inc T.EDT

Paradigm needs to update…

[mercedesman]

Given all the good things happening 

Example:

• increasing rate of enrollment
• ARC validation 
• Sam Amory 
• DIMI participant # 2
• etc. 

they were at 75% odds of PMX approval ( Feeling a need to show some conservatism I guess)

But given " greatly exceeding Expectations " in the Tigris "confirmatory trial" 

I think they should show more confidence with even higher odds of approval   

MM

[Gorf79]

You are better off pretending they don't exist like me. The share price move will soon be jarring. Paradigm is irrelevant!

[smartsob]

The last research note I have from Paradigm is dated Feb 7, 2020. The rating was speculative buy with a $4.00 target. PMX only at that time. The note and its target price are no longer relevant.

[mercedesman]

Ssob  Paradigm has issued at least two updates since then  they lowered the target price due to trial delays/ COVID, yada yada  I see the latest release as being out of step with recent positive announcements.  Ali can probably get you a little more current.  But Gorf is likely right. There is (1) the SP, (2) the reality, with the latest developments and LT

[cashworx22]

This post has been removed in accordance with Community Policy

[mercedesman]

...their target price for Spectral and odds of FDA approval of PMX...especially given all the good things happening of late... Example: Breakthrough Device Designation increasing rate of enrollment ARC validation  Sam Amory  DIMI participant # 2  (all participants identified?) etc.  Paradim was forcasting 75% odds of PMX approval ( I'm

[Gorf79]

MM. Spectral has never seemed to have much of a partnership with their various analysts over the years. I've seen it evidenced over 18 years of futility in their analyst coverage. You would get a bang up job on the initial coverage and then they'd fade into obscurity just like Paradigm has, failing to report at all on the progress they are making. If Paradigm  won't update

[mercedesman]

"I don't think Spectral cares much about its analyst coverage. They don't need or want any more shareholders. The end game is nigh. Analysts are a waste of time if you know precisely where you are headed."  Gorf All well an good, if there were no existing shareholders, and no need to raise any money in the interim, in order to get them through the end-game (to checkmate)

[Gorf79]

Unfortunately waiting on analyst coverage is pi$$ing in to the wind. I doubt they have time or the inclination to bring a new analyst, or analysts,  up to speed. Paradigm coverage seems to have gone by the wayside. And they don't, and never have, cared much about retail opinion.